EA036615B1 - Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке - Google Patents

Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке Download PDF

Info

Publication number
EA036615B1
EA036615B1 EA201591304A EA201591304A EA036615B1 EA 036615 B1 EA036615 B1 EA 036615B1 EA 201591304 A EA201591304 A EA 201591304A EA 201591304 A EA201591304 A EA 201591304A EA 036615 B1 EA036615 B1 EA 036615B1
Authority
EA
Eurasian Patent Office
Prior art keywords
tumor
ssrp1
cells
cancer
fact
Prior art date
Application number
EA201591304A
Other languages
English (en)
Russian (ru)
Other versions
EA201591304A1 (ru
Inventor
Катерина ГУРОВА
Original Assignee
Общество С Ограниченной Ответственностью "Инкурон"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Инкурон" filed Critical Общество С Ограниченной Ответственностью "Инкурон"
Publication of EA201591304A1 publication Critical patent/EA201591304A1/ru
Publication of EA036615B1 publication Critical patent/EA036615B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EA201591304A 2013-02-11 2014-02-11 Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке EA036615B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763266P 2013-02-11 2013-02-11
US201361883802P 2013-09-27 2013-09-27
PCT/US2014/015854 WO2014124454A1 (en) 2013-02-11 2014-02-11 Use of facilitates chromatin transcription complex (fact) in cancer

Publications (2)

Publication Number Publication Date
EA201591304A1 EA201591304A1 (ru) 2016-01-29
EA036615B1 true EA036615B1 (ru) 2020-11-30

Family

ID=51300203

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591304A EA036615B1 (ru) 2013-02-11 2014-02-11 Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке

Country Status (6)

Country Link
US (1) US10386370B2 (https=)
EP (1) EP2954331B1 (https=)
JP (1) JP6576249B2 (https=)
CN (1) CN104981697B (https=)
EA (1) EA036615B1 (https=)
WO (1) WO2014124454A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108333366B (zh) * 2018-01-26 2020-06-12 南通大学附属医院 一种实验性监测肝细胞恶性转化过程大鼠模型的建立方法
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途
CN113721020B (zh) * 2021-09-14 2022-06-24 大连医科大学附属第二医院 Ctsf在非小细胞肺癌诊断中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110183336A1 (en) * 2007-10-26 2011-07-28 The Regents Of The University Of California Method to Predict Responsiveness of Breast Cancer to Polyamine-Type Chemotherapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2715680A1 (de) 1977-04-07 1978-10-12 Henkel Kgaa Haarfaerbemittel
CA2992643C (en) 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US20100047783A1 (en) 2006-06-20 2010-02-25 El-Diery Wafik S Small molecule modulators of p53 family signaling
JP5583117B2 (ja) 2008-05-14 2014-09-03 ユニバーシティー ヘルス ネットワーク 非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー
EP2294186B1 (en) 2008-05-20 2019-10-09 Incuron, Inc. Inducing cell death by inhibiting adaptive heat shock response
US20100081666A1 (en) 2008-07-14 2010-04-01 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US20100331210A1 (en) 2009-05-29 2010-12-30 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
US9169207B2 (en) 2012-03-27 2015-10-27 Incuron, Llc Curaxins for use in treating carcinogen-induced cancer
US20140066465A1 (en) 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110183336A1 (en) * 2007-10-26 2011-07-28 The Regents Of The University Of California Method to Predict Responsiveness of Breast Cancer to Polyamine-Type Chemotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BELOTSERKOVSKAYA, R. et al. FACT Facilitates Transcription-Dependent Nucleosome Alteration. Science. 22 August 2003, Vol. 301, No. 5636; pages 1090-1093. page 1090, left column, third paragraph to middle column, first paragraph. *
GARCIA, H. et al. Expression Of FACT In Mammalian Tissues Suggests Its Role In Maintaining Of Undifferentated State Of Cells. Oncotarget. 13 October 2011; Vol. 2, No. 10; pages 783-796; page 10, figure 5; page 10, right column, fifth paragraph to page 11, left column, first paragraph. *
GARCIA, H. et al. Facilitates Chromatin Transctiption Complex Is A'Accelerator' Of Tumor Transformation And Potential Marker And Target Of Aggressive Cancers. Cell Reports. 11 July 2013; Vol. 4, No. 1; pages 159-73. DOI: 10.1016/j.celrep.2013.06.013. *

Also Published As

Publication number Publication date
WO2014124454A1 (en) 2014-08-14
HK1218953A1 (en) 2017-03-17
US20160033515A1 (en) 2016-02-04
EP2954331B1 (en) 2018-03-28
JP2016514248A (ja) 2016-05-19
EP2954331A1 (en) 2015-12-16
EA201591304A1 (ru) 2016-01-29
EP2954331A4 (en) 2016-08-31
US10386370B2 (en) 2019-08-20
JP6576249B2 (ja) 2019-09-18
CN104981697A (zh) 2015-10-14
CN104981697B (zh) 2017-08-04

Similar Documents

Publication Publication Date Title
Schaner et al. Gene expression patterns in ovarian carcinomas
JP6900314B2 (ja) 膀胱癌の治療、診断、及び予後判定方法
US20200327962A1 (en) Statistical ai for advanced deep learning and probabilistic programing in the biosciences
JP5971769B2 (ja) アントラサイクリン療法を用いて乳癌を処置する方法
KR20170094165A (ko) 화학요법-내성 암을 치료 및 진단하는 조성물 및 방법
JP2015530072A (ja) ゲムシタビン療法による乳癌の治療方法
JP7236164B2 (ja) 治療法に対する応答を予測する薬剤及び方法
WO2013052480A1 (en) Marker-based prognostic risk score in colon cancer
US20230235408A1 (en) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
Yang et al. Overexpression of CD151 predicts prognosis in patients with resected gastric cancer
Al‐Sohaily et al. Loss of special AT‐rich sequence‐binding protein 1 (SATB 1) predicts poor survival in patients with colorectal cancer
JP7741831B2 (ja) 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
Chen et al. Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response
EP2954331B1 (en) Use of facilitates chromatin transcription complex (fact) in cancer
US20140100188A1 (en) Phenotyping tumor-infiltrating leukocytes
Zhu et al. Heterogeneous distribution pattern of CD3+ tumor-infiltrated lymphocytes (TILs) and high combined positive score (CPS) favored the prognosis of resected early stage small-cell lung cancer
EP2457096A2 (en) Phenotyping tumor-infiltrating leukocytes
JP2023535811A (ja) ＨＥＲ２陽性乳癌を患う患者の予後診断を行うｉｎ ｖｉｔｒｏ方法
KR102431271B1 (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
US11851709B2 (en) HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy
HK1218953B (en) Use of facilitates chromatin transcription complex (fact) in cancer
Maloney The identification and evaluation of predictive and prognostic biomarkers in order to personalise treatment pathways for patients diagnosed with pancreatic cancer.
Scerri Herceptin® resistance in breast cancer: a pathwaybased approach
WO2017151768A1 (en) Data processing and classification for determining an effectiveness score for immunotherapy
Bownes Evaluating the utility of gene expression data from patient-matched samples for studying breast cancer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM